All In Biotech

Drug Trial Radar · NCT06755684

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 7, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Peng ZhangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Conditions

  • EGFR
  • Non-Small Cell Lung Cancer
  • Locally Advanced Non-Small Cell Lung Cancer
  • Pemetrexed
  • Carboplatin
  • Bevacizumab
  • Antineoplastic Agents
  • Tyrosine Kinase Inhibitor

Interventions

  • Befotertinib combined BevacizumabDrug

    Befotertinib combined Bevacizumab

  • Befotertinib combined platinum-based double chemotherapyDrug

    Befotertinib combined platinum-based double chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major pathologic response (MPR)Time frame: up to 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.